Enlivex Therapeutics Ltd. Form 6-K Summary
Business Context and Reporting Period
This Form 6-K was filed by Enlivex Therapeutics Ltd., an Israeli company, on September 13, 2023. The filing serves to announce the scheduling of the Company's 2023 Annual General Meeting of Shareholders.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a procedural notice regarding a shareholder meeting and does not contain financial statements or performance data.
Material Changes
No material financial changes versus the prior comparable period are reported in this document.
Guidance, Outlook, and Management Commentary
The Company announced that the 2023 Annual General Meeting will be held on Thursday, October 26, 2023, at 7:00 p.m. Israel time. The meeting location is the Company's offices at 14 Einstein Street, Nes Ziona, Israel 7403618. The filing incorporates the proxy statement and proxy card as Exhibits 99.1 and 99.2. No specific business outlook, risk factors, or unusual items are detailed in the body of this report.
Key Facts for Investor Verification
- Verify the date and time of the Annual General Meeting: October 26, 2023, at 7:00 p.m. Israel time.
- Review the attached Proxy Statement (Exhibit 99.1) for details on matters to be voted upon.
- Confirm the physical location of the meeting at 14 Einstein Street, Nes Ziona, Israel.
- Note that this filing contains no financial performance data for the period.